HELEN HESLOP

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleDirector
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Medicine
    DivisionMedicine-Hematology & Oncology


    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Research 
    Collapse research activities and funding
    R01HL055703     (HESLOP, HELEN E)Sep 30, 1995 - Nov 14, 1997
    NIH/NHLBI
    DOUBLE GENE MARKING TO ANALYZE STEM CELLS IN CHILDREN
    Role: Principal Investigator

    P01CA094237     (HESLOP, HELEN E)Dec 1, 2001 - Sep 30, 2010
    NIH/NCI
    Enhancing T Cell Therapy of Cancer
    Role: Principal Investigator

    T32DK064717     (HESLOP, HELEN E)Jul 1, 2003 - Jun 30, 2008
    NIH/NIDDK
    Training in Cell and Gene Therapy
    Role: Principal Investigator

    T32HL092332     (HESLOP, HELEN E)Jul 1, 2003 - Jun 30, 2018
    NIH/NHLBI
    Training In Cell and Gene Therapy
    Role: Principal Investigator

    P50CA126752     (HESLOP, HELEN E)Apr 1, 2007 - Sep 30, 2010
    NIH/NCI
    SPORE in Lymphoma
    Role: Principal Investigator

    P30CA125123     (OSBORNE, C KENT)Jul 1, 2007 - Sep 29, 2012
    NIH/NCI
    Baylor College of Medicine Cancer Center-Cancer Center Support Grant
    Role: Co-Principal Investigator

    U10HL108945     (HESLOP, HELEN E)Aug 8, 2011 - Jun 30, 2017
    NIH/NHLBI
    Anti-viral and antileukemic T-cell therapy as prophylaxis after HSCT
    Role: Principal Investigator

    UG1HL108945     (HESLOP, HELEN E)Aug 8, 2011 - Jun 30, 2024
    NIH/NHLBI
    Targeting HIV and EBV Antigens in Patients with HIV Lymphoma
    Role: Principal Investigator

    R13TR002018     (HESLOP, HELEN E)May 1, 2017 - Apr 30, 2018
    NIH/NCATS
    American Society of Gene & Cell Therapy (ASGCT) 20th Annual Meeting
    Role: Principal Investigator

    R13TR002411     (HESLOP, HELEN E)Feb 15, 2018 - Jan 31, 2021
    NIH/NCATS
    American Society of Gene & Cell Therapy (ASGCT) 21st Annual Meeting
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mo F, Mamonkin M, Brenner MK, Heslop HE. Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 Jan 31. PMID: 33536140.
      Citations:    Fields:    
    2. Vasileiou S, Lulla PD, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL, Bilgi M, Wang T, Wu MJ, Kamble R, Ramos CA, Rouce RH, Zeng Z, Gee AP, Grilley BJ, Vera JF, Bollard CM, Brenner MK, Heslop HE, Rooney CM, Leen AM, Carrum G. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 Jan 28; JCO2002224. PMID: 33507803.
      Citations:    Fields:    
    3. Heslop HE, Sharma S, Rooney CM. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. J Clin Oncol. 2021 Feb 10; 39(5):514-524. PMID: 33434061.
      Citations:    Fields:    
    4. Lulla P, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, Lulla S, Carrum G, Ramos CA, Kamble R, Hill LC, Randhawa JK, Gottschalk S, Krance R, Tao W, Wu M, Robertson C, Gee AP, Chung BM, Grilley B, Brenner M, Heslop H, Vera JF, Leen AM. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant. Blood. 2020 Dec 03. PMID: 33270816.
      Citations:    Fields:    
    5. Ataca Atilla P, McKenna MK, Tashiro H, Srinivasan M, Mo F, Watanabe N, Simons BW, McLean Stevens A, Redell MS, Heslop HE, Mamonkin M, Brenner MK, Atilla E. Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2). PMID: 32938629.
      Citations:    Fields:    
    6. Lulla PD, Tzannou I, Vasileiou S, Carrum G, Ramos CA, Kamble R, Wang T, Wu M, Bilgi M, Gee AP, Mukhi S, Chung B, Wang L, Watanabe A, Kuvalekar M, Jeong M, Li Y, Ketkar S, French-Kim M, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554). PMID: 32727914.
      Citations: 1     Fields:    
    7. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 Nov 10; 38(32):3794-3804. PMID: 32701411.
      Citations: 9     Fields:    
    8. Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549. PMID: 32669548.
      Citations: 4     Fields:    Translation:HumansCells
    9. Mo F, Watanabe N, McKenna MK, Hicks MJ, Srinivasan M, Gomes-Silva D, Atilla E, Smith T, Ataca Atilla P, Ma R, Quach D, Heslop HE, Brenner MK, Mamonkin M. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63. PMID: 32661440.
      Citations: 4     Fields:    
    10. Heslop HE. Sensitizing Burkitt lymphoma to EBV-CTLs. Blood. 2020 05 21; 135(21):1822-1823. PMID: 32437562.
      Citations:    Fields:    
    11. Mo F, Heslop HE, Mamonkin M. CRISPR-Edited Immune Effectors: The End of the Beginning. Mol Ther. 2020 04 08; 28(4):995-996. PMID: 32203679.
      Citations:    Fields:    Translation:HumansCells
    12. Levine JE, Antin JH, Allen CE, Burroughs LM, Cooke KR, Devine S, Heslop H, Nakamura R, Talano JA, Yanik G, DiFronzo N. Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2020 05; 26(5):e94-e100. PMID: 32035274.
      Citations:    Fields:    
    13. Naik S, Eckstein O, Sasa G, Heslop HE, Krance RA, Allen C, Martinez C. Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020 03; 188(6):e84-e87. PMID: 31989587.
      Citations:    Fields:    Translation:Humans
    14. Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance RA, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350. PMID: 31558475.
      Citations: 3     Fields:    Translation:HumansCells
    15. Naik S, Martinez CA, Omer B, Sasa G, Yassine K, Allen CE, Kamdar K, Orth R, Wu M, Leung K, Gottschalk S, Brenner MK, Heslop HE, Krance RA. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695. PMID: 31511228.
      Citations:    Fields:    Translation:Humans
    16. Tzannou I, Watanabe A, Naik S, Daum R, Kuvalekar M, Leung KS, Martinez C, Sasa G, Wu M, Gee AP, Krance RA, Gottschalk S, Heslop HE, Omer B. "Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Adv. 2019 09 10; 3(17):2571-2580. PMID: 31481503.
      Citations: 6     Fields:    Translation:HumansCells
    17. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 12; 25(12):2305-2321. PMID: 31446199.
      Citations: 16     Fields:    
    18. Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct; 21(5):e13145. PMID: 31301099.
      Citations: 2     Fields:    Translation:HumansCells
    19. Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Br J Haematol. 2019 10; 187(2):206-218. PMID: 31219185.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    20. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant. 2019 11; 54(11):1868-1880. PMID: 31092900.
      Citations: 11     Fields:    
    21. Steffin DHM, Heslop HE. Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells. Mol Ther. 2019 05 08; 27(5):900-901. PMID: 31005599.
      Citations:    Fields:    Translation:HumansCells
    22. Leung W, Heslop HE. Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR. Cancer Immunol Res. 2019 04; 7(4):528-533. PMID: 30936089.
      Citations: 5     Fields:    Translation:HumansCells
    23. Hill L, Lulla P, Heslop HE. CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm. Adv Cell Gene Ther. 2019 Jul; 2(3). PMID: 31777773.
      Citations:    
    24. Heslop HE, Shpall EJ. Harmonizing Immune Effector Toxicity Reporting. Biol Blood Marrow Transplant. 2019 04; 25(4):e121-e122. PMID: 30615980.
      Citations: 1     Fields:    Translation:HumansCells
    25. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 03; 25(3):e76-e85. PMID: 30576834.
      Citations: 14     Fields:    Translation:Humans
    26. McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361. PMID: 30262660.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    27. Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737. PMID: 30309819.
      Citations: 32     Fields:    Translation:HumansCells
    28. Nishiyama-Fujita Y, Kawana-Tachikawa AI, Ono T, Tanaka Y, Kato T, Heslop HE, Morio T, Takahashi S. Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium. Cytotherapy. 2018 09; 20(9):1182-1190. PMID: 30122653.
      Citations: 2     Fields:    Translation:HumansCells
    29. Shum T, Heslop HE. A backpack revs up T-cell activity. Nat Biotechnol. 2018 08 06; 36(8):702-703. PMID: 30080841.
      Citations:    Fields:    Translation:HumansCells
    30. Lulla PD, Hill LC, Ramos CA, Heslop HE. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018 May; 16(5):375-386. PMID: 29851933.
      Citations: 4     Fields:    Translation:HumansCells
    31. Chinn IK, Eckstein OS, Peckham-Gregory EC, Goldberg BR, Forbes LR, Nicholas SK, Mace EM, Vogel TP, Abhyankar HA, Diaz MI, Heslop HE, Krance RA, Martinez CA, Nguyen TC, Bashir DA, Goldman JR, Stray-Pedersen A, Pedroza LA, Poli MC, Aldave-Becerra JC, McGhee SA, Al-Herz W, Chamdin A, Coban-Akdemir ZH, Jhangiani SN, Muzny DM, Cao TN, Hong DN, Gibbs RA, Lupski JR, Orange JS, McClain KL, Allen CE. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100. PMID: 29632024.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    32. Yanir AD, Hanson IC, Shearer WT, Noroski LM, Forbes LR, Seeborg FO, Nicholas S, Chinn I, Orange JS, Rider NL, Leung KS, Naik S, Carrum G, Sasa G, Hegde M, Omer BA, Ahmed N, Allen CE, Khaled Y, Wu MF, Liu H, Gottschalk SM, Heslop HE, Brenner MK, Krance RA, Martinez CA. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2018 08; 24(8):1643-1650. PMID: 29630926.
      Citations: 7     Fields:    Translation:Humans
    33. Yanir AD, Martinez CA, Sasa G, Leung K, Gottschalk S, Omer B, Ahmed N, Hegde M, Eunji J, Liu H, Heslop HE, Brenner MK, Krance RA, Naik S. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431. PMID: 29550628.
      Citations: 1     Fields:    Translation:Humans
    34. Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139. PMID: 29315015.
      Citations: 36     Fields:    Translation:HumansCells
    35. Heslop HE, Brenner MK. Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther. 2018 01 03; 26(1):1-2. PMID: 29273500.
      Citations:    Fields:    Translation:HumansCells
    36. Ngwube A, Hanson IC, Orange J, Rider NL, Seeborg F, Shearer W, Noroski L, Nicholas S, Forbes L, Leung K, Sasa G, Naik S, Hegde M, Omer B, Ahmed N, Allen C, Gottschalk S, Wu MF, Liu H, Brenner M, Heslop H, Krance R, Martinez C. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541. PMID: 29196075.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    37. Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471. PMID: 28805662.
      Citations: 72     Fields:    Translation:HumansCellsCTClinical Trials
    38. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557. PMID: 28783452.
      Citations: 72     Fields:    Translation:HumansCellsCTClinical Trials
    39. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101. PMID: 28426845.
      Citations: 94     Fields:    Translation:HumansCellsCTClinical Trials
    40. Rouce RH, Heslop HE. Equal opportunity CAR T cells. Blood. 2017 06 22; 129(25):3275-3277. PMID: 28642356.
      Citations: 1     Fields:    Translation:HumansCells
    41. Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224. PMID: 28602436.
      Citations: 65     Fields:    Translation:HumansCells
    42. Mamonkin M, Heslop HE. Exhausting alloreactivity of donor-derived CAR T cells. Nat Med. 2017 02 07; 23(2):147-148. PMID: 28170385.
      Citations: 2     Fields:    Translation:HumansCells
    43. Lulla P, Heslop HE. Fall of the mutants: T cells targeting BCR-ABL. Blood. 2017 02 02; 129(5):539-540. PMID: 28153834.
      Citations:    Fields:    Translation:HumansCells
    44. Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258. PMID: 28129119.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    45. Lulla P, Heslop HE. Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):390-396. PMID: 27913506.
      Citations: 3     Fields:    Translation:HumansCells
    46. Rouce RH, Sharma S, Huynh M, Heslop HE. Recent advances in T-cell immunotherapy for haematological malignancies. Br J Haematol. 2017 03; 176(5):688-704. PMID: 27897332.
      Citations: 9     Fields:    Translation:HumansCells
    47. Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016; 5(12):e1253656. PMID: 28180032.
      Citations:    
    48. Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96. PMID: 27270177.
      Citations: 72     Fields:    Translation:HumansCellsCTClinical Trials
    49. Rouce RH, Heslop HE. Forecasting Cytokine Storms with New Predictive Biomarkers. Cancer Discov. 2016 06; 6(6):579-80. PMID: 27261481.
      Citations: 6     Fields:    Translation:HumansCells
    50. Bollard CM, Heslop HE. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016 06 30; 127(26):3331-40. PMID: 27207801.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    51. Kimmelman J, Hyun I, Benvenisty N, Caulfield T, Heslop HE, Murry CE, Sipp D, Studer L, Sugarman J, Daley GQ. Policy: Global standards for stem-cell research. Nature. 2016 05 19; 533(7603):311-3. PMID: 27193661.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    52. Kimmelman J, Heslop HE, Sugarman J, Studer L, Benvenisty N, Caulfield T, Hyun I, Murry CE, Sipp D, Daley GQ. New ISSCR guidelines: clinical translation of stem cell research. Lancet. 2016 May 14; 387(10032):1979-81. PMID: 27179752.
      Citations: 9     Fields:    Translation:HumansPHPublic Health
    53. Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, Breuer CK, Caulfield T, Cedars MI, Frey-Vasconcells J, Heslop HE, Jin Y, Lee RT, McCabe C, Munsie M, Murry CE, Piantadosi S, Rao M, Rooke HM, Sipp D, Studer L, Sugarman J, Takahashi M, Zimmerman M, Kimmelman J. Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. Stem Cell Reports. 2016 06 14; 6(6):787-797. PMID: 27185282.
      Citations: 38     Fields:    Translation:HumansCells
    54. Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR, Amrolia P, Lucchini G, Bunin N, Heimall J, Klein OR, Gennery AR, Slatter MA, Vickers MA, Orange JS, Heslop HE, Bollard CM, Keller MD. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1. PMID: 26920464.
      Citations: 29     Fields:    Translation:HumansCells
    55. Zhou X, Naik S, Dakhova O, Dotti G, Heslop HE, Brenner MK. Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2016 Apr; 24(4):823-31. PMID: 26708005.
      Citations: 11     Fields:    Translation:HumansCells
    56. Chang EC, Liu H, West JA, Zhou X, Dakhova O, Wheeler DA, Heslop HE, Brenner MK, Dotti G. Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45. PMID: 26639404.
      Citations: 7     Fields:    Translation:HumansCells
    57. Ramos CA, Heslop HE, Brenner MK. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83. PMID: 26332003.
      Citations: 39     Fields:    Translation:HumansCells
    58. Manzo T, Heslop HE, Rooney CM. Antigen-specific T cell therapies for cancer. Hum Mol Genet. 2015 Oct 15; 24(R1):R67-73. PMID: 26160910.
      Citations: 12     Fields:    Translation:HumansCells
    59. Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13. PMID: 25977584.
      Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
    60. Naik S, Heslop HE. Engineering haploidentical transplants. Bone Marrow Transplant. 2015 Jul; 50(7):884-5. PMID: 25961777.
      Citations:    Fields:    Translation:Humans
    61. Cohen JI, Niemela JE, Stoddard JL, Pittaluga S, Heslop H, Jaffe ES, Dowdell K. Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1). J Clin Immunol. 2015 Jul; 35(5):445-8. PMID: 25947952.
      Citations: 7     Fields:    Translation:HumansCells
    62. Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16. PMID: 25940712.
      Citations: 78     Fields:    Translation:HumansAnimalsCells
    63. Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, Bollard CM. CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015 Apr 29; 7(285):285ra63. PMID: 25925682.
      Citations: 34     Fields:    Translation:HumansCells
    64. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96. PMID: 25800760.
      Citations: 233     Fields:    Translation:HumansCellsCTClinical Trials
    65. Naik S, Martinez C, Leung K, Sasa G, Nguyen NY, Wu MF, Gottschalk S, Brenner M, Heslop H, Krance R. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72. PMID: 25765555.
      Citations: 3     Fields:    Translation:Humans
    66. Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, Barth P, Dotti G, Savoldo B. Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest. 2015 Jan; 125(1):157-68. PMID: 25415440.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    67. Rouce RH, Louis CU, Heslop HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol. 2014 Nov; 21(6):476-81. PMID: 25159713.
      Citations: 7     Fields:    Translation:HumansCells
    68. Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, Horowitz MM. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2015 Feb; 21(2):202-24. PMID: 25445636.
      Citations: 7     Fields:    Translation:Humans
    69. Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol Ther. 2015 Jan; 23(1):179-83. PMID: 25266309.
      Citations: 13     Fields:    Translation:HumansCells
    70. Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, Powell D, Ribas A, Rosenberg S, Sadelain M, Till B, Patterson AP, Jambou RC, Rosenthal E, Gargiulo L, Montgomery M, Kohn DB. T-cell immunotherapy: looking forward. Mol Ther. 2014 Sep; 22(9):1564-74. PMID: 25186558.
      Citations: 24     Fields:    Translation:HumansCells
    71. Bollard CM, Heslop HE, Rooney CM. Reply to S. Yuan et al. J Clin Oncol. 2014 Sep 01; 32(25):2820-1. PMID: 25049328.
      Citations:    Fields:    Translation:HumansCells
    72. Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83. PMID: 24964991.
      Citations: 111     Fields:    Translation:HumansCellsCTClinical Trials
    73. Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, Lu X, Ripple K, Centanni JM, Hall C, Hsu D, Couture LA, Gupta S, Gee AP, Heslop HE, Leen AM, Rooney CM, Vera JF. Optimizing the production of suspension cells using the G-Rex "M" series. Mol Ther Methods Clin Dev. 2014; 1:14015. PMID: 26015959.
      Citations:    
    74. Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203. PMID: 24714353.
      Citations: 21     Fields:    Translation:HumansCells
    75. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B, Dotti G. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9. PMID: 24782509.
      Citations: 146     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    76. Kamble RT, Scholoff A, Obi AG, Heslop HE, Brenner MK, Carrum G. Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD. Bone Marrow Transplant. 2014 Jul; 49(7):986-7. PMID: 24777189.
      Citations:    Fields:    Translation:Humans
    77. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti G. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905. PMID: 24753538.
      Citations: 64     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    78. Hildebrandt M, Peggs K, Uharek L, Bollard CM, Heslop HE. Immunotherapy: opportunities, risks and future perspectives. Cytotherapy. 2014 Apr; 16(4 Suppl):S120-9. PMID: 24629797.
      Citations: 2     Fields:    Translation:Humans
    79. Papadopoulou A, Krance RA, Allen CE, Lee D, Rooney CM, Brenner MK, Leen AM, Heslop HE. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138. PMID: 24651135.
      Citations: 12     Fields:    Translation:HumansCells
    80. Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220. PMID: 24732709.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    81. Leen AM, Heslop HE, Brenner MK. Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29. PMID: 24517423.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    82. Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014 Apr 15; 20(8):2215-25. PMID: 24573552.
      Citations: 75     Fields:    Translation:HumansCellsCTClinical Trials
    83. Heslop HE. Combining drugs and biologics to treat nasopharyngeal cancer. Mol Ther. 2014 Jan; 22(1):8-9. PMID: 24384910.
      Citations: 2     Fields:    Translation:Humans
    84. Rooney CM, Leen AM, Vera JF, Heslop HE. T lymphocytes targeting native receptors. Immunol Rev. 2014 Jan; 257(1):39-55. PMID: 24329788.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    85. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808. PMID: 24344220.
      Citations: 142     Fields:    Translation:HumansCellsCTClinical Trials
    86. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633. PMID: 24213558.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    87. Cox JE, Campos S, Wu J, May R, Liu H, Ramos CA, Carrum G, Heslop HE, Brenner MK, Kamble RT. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22. PMID: 24096822.
      Citations: 2     Fields:    Translation:Humans
    88. Cruz CR, Lam S, Hanley PJ, Bear AS, Langston C, Cohen AJ, Liu H, Martinez CA, Krance RA, Heslop HE, Rooney CM, Hanson IC, Bollard CM. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013 Oct; 174(1):89-96. PMID: 23763437.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    89. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73. PMID: 24030379.
      Citations: 168     Fields:    Translation:HumansCellsCTClinical Trials
    90. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Gottachalk S, Yvon E, Ahmed N. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101. PMID: 23939024.
      Citations: 98     Fields:    Translation:HumansAnimalsCells
    91. Heslop HE. Genetic engineering of T-cell receptors: TCR takes to titin. Blood. 2013 Aug 08; 122(6):853-4. PMID: 23929832.
      Citations: 1     Fields:    Translation:HumansCells
    92. Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids. 2013 Jul 09; 2:e105. PMID: 23839099.
      Citations:    
    93. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21. PMID: 23783429.
      Citations: 74     Fields:    Translation:HumansCellsCTClinical Trials
    94. Arber C, Abhyankar H, Heslop HE, Brenner MK, Liu H, Dotti G, Savoldo B. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther. 2013 Sep; 20(9):958-62. PMID: 23698740.
      Citations: 17     Fields:    Translation:HumansCells
    95. Heslop HE. Pharmacotherapy versus T lymphocytes for CMV. Blood. 2013 May 02; 121(18):3544-5. PMID: 23640995.
      Citations: 2     Fields:    Translation:HumansCells
    96. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23. PMID: 23610374.
      Citations: 164     Fields:    Translation:HumansCells
    97. Engels EA, Savoldo B, Pfeiffer RM, Costello R, Zingone A, Heslop HE, Landgren O. Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. Transplantation. 2013 Feb 15; 95(3):519-26. PMID: 23222884.
      Citations: 5     Fields:    Translation:HumansCells
    98. Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, Rooney CM. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76. PMID: 23211628.
      Citations: 24     Fields:    Translation:HumansCells
    99. Heslop HE, Leen AM. T-cell therapy for viral infections. Hematology Am Soc Hematol Educ Program. 2013; 2013:342-7. PMID: 24319202.
      Citations: 11     Fields:    Translation:HumansCells
    100. Chakraborty R, Mahendravada A, Perna SK, Rooney CM, Heslop HE, Vera JF, Savoldo B, Dotti G. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7. PMID: 23242592.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    101. Gerdemann U, Keukens L, Keirnan JM, Katari UL, Nguyen CT, de Pagter AP, Ramos CA, Kennedy-Nasser A, Gottschalk SM, Heslop HE, Brenner MK, Rooney CM, Leen AM. Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood. 2013 Jan 03; 121(1):207-18. PMID: 23152545.
      Citations: 31     Fields:    Translation:HumansCells
    102. Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin Cancer Res. 2013 Jan 01; 19(1):106-17. PMID: 23149818.
      Citations: 36     Fields:    Translation:HumansCells
    103. Fernandez Vina M, Heslop HE, Barker JN. New approaches in alternative donor transplantation. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S91-6. PMID: 23110984.
      Citations: 1     Fields:    Translation:Humans
    104. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012 Aug; 20(8):1622-32. PMID: 22801446.
      Citations: 80     Fields:    Translation:HumansCells
    105. Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012 Sep; 9(9):510-9. PMID: 22801669.
      Citations: 74     Fields:    Translation:HumansCells
    106. Heslop HE. Equal-opportunity treatment of EBV-PTLD. Blood. 2012 Mar 15; 119(11):2436-8. PMID: 22422813.
      Citations:    Fields:    
    107. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, Leen AM, Bollard CM, Rooney CM, Heslop HE, Gottschalk S, Ahmed N. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68. PMID: 22306904.
      Citations: 28     Fields:    Translation:HumansCells
    108. Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012 Feb; 20(2):246-9. PMID: 22297819.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    109. Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, Bollard CM, Rooney CM. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 Jan; 14(1):7-11. PMID: 22172091.
      Citations: 15     Fields:    Translation:HumansCells
    110. Martinez CA, Shah S, Shearer WT, Rosenblatt HM, Paul ME, Chinen J, Leung KS, Kennedy-Nasser A, Brenner MK, Heslop HE, Liu H, Wu MF, Hanson IC, Krance RA. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83. PMID: 22078471.
      Citations: 24     Fields:    Translation:Humans
    111. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83. PMID: 22047558.
      Citations: 493     Fields:    Translation:HumansCellsCTClinical Trials
    112. Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, Fischer G, Poulton K, Wacker K, Hurley CK, Noreen H, Sacchi N. Definitions of histocompatibility typing terms. Blood. 2011 Dec 01; 118(23):e180-3. PMID: 22001389.
      Citations: 11     Fields:    Translation:Humans
    113. Shaffer DR, Sheehan AM, Yi Z, Rodgers CC, Bollard CM, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61. PMID: 21994111.
      Citations:    Fields:    Translation:HumansCells
    114. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, Liu H, Wu MF, Gee AP, Mei Z, Rooney CM, Heslop HE, Brenner MK. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6. PMID: 21984804.
      Citations: 353     Fields:    Translation:HumansCellsCTClinical Trials
    115. Heslop HE. TCR expression; quantitative easing by CD3. Blood. 2011 Sep 29; 118(13):3452-3. PMID: 21960676.
      Citations:    Fields:    
    116. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68. PMID: 21915103.
      Citations: 25     Fields:    Translation:HumansCells
    117. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66. PMID: 21908573.
      Citations: 31     Fields:    Translation:HumansCells
    118. Okur FV, Yvon E, Biagi E, Dotti G, Carrum G, Heslop H, Mims MP, Fratantoni JC, Peshwa MV, Li L, Brenner MK. Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. Cytotherapy. 2011 Oct; 13(9):1128-39. PMID: 21745159.
      Citations: 4     Fields:    Translation:HumansCells
    119. Heslop H. Getting personal with melanoma. Clin Cancer Res. 2011 Jul 01; 17(13):4189-91. PMID: 21712453.
      Citations: 1     Fields:    Translation:HumansCells
    120. Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, Fischer G, Poulton K, Wacker K, Hurley CK, Noreen H, Sacchi N. Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. Hum Immunol. 2011 Dec; 72(12):1214-6. PMID: 21723898.
      Citations: 6     Fields:    Translation:HumansCells
    121. Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011 Jun; 16(3):274-80. PMID: 21467936.
      Citations: 13     Fields:    Translation:Humans
    122. Salsman VS, Chow KK, Shaffer DR, Kadikoy H, Li XN, Gerken C, Perlaky L, Metelitsa LS, Gao X, Bhattacharjee M, Hirschi K, Heslop HE, Gottschalk S, Ahmed N. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One. 2011; 6(5):e20267. PMID: 21647415.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    123. Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, Demmler-Harrison G, Heslop HE, Rooney CM, Gottschalk S, Bollard CM. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011 Sep; 13(8):976-86. PMID: 21539497.
      Citations: 19     Fields:    Translation:HumansCells
    124. Heslop HE. A less sour sweet; blocking galectin. Blood. 2011 Apr 21; 117(16):4165-6. PMID: 21511962.
      Citations: 1     Fields:    
    125. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6. PMID: 21540550.
      Citations: 373     Fields:    Translation:HumansCells
    126. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Straus SE. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49. PMID: 21454450.
      Citations: 75     Fields:    Translation:HumansCells
    127. Ngo MC, Rooney CM, Howard JM, Heslop HE. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011 Apr 15; 20(R1):R93-9. PMID: 21415041.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    128. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M, Heslop HE. CARs on track in the clinic. Mol Ther. 2011 Mar; 19(3):432-8. PMID: 21358705.
      Citations: 56     Fields:    Translation:Humans
    129. Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJ. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol. 2011 Apr; 153(1):76-82. PMID: 21323890.
      Citations: 16     Fields:    Translation:Humans
    130. Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62. PMID: 21278353.
      Citations: 35     Fields:    Translation:HumansCells
    131. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Heslop HE, Brenner MK, Krance RA. Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51. PMID: 21108446.
      Citations: 3     Fields:    Translation:Humans
    132. Bonini C, Brenner MK, Heslop HE, Morgan RA. Genetic modification of T cells. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S15-20. PMID: 21195304.
      Citations: 18     Fields:    Translation:HumansCells
    133. Horwitz EM, Horowitz MM, DiFronzo NL, Kohn DB, Heslop HE. Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2011 Feb; 17(2):192-6. PMID: 21182973.
      Citations: 1     Fields:    Translation:Humans
    134. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010 Nov-Dec; 33(9):983-90. PMID: 20948438.
      Citations: 70     Fields:    Translation:HumansCellsCTClinical Trials
    135. Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, Gottschalk S, Savoldo B, Dotti G, Louis CU, Leen AM, Gee AP, Rooney CM, Brenner MK, Bollard CM, Heslop HE. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct; 12(6):743-9. PMID: 20429793.
      Citations: 24     Fields:    Translation:Cells
    136. Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, Rooney CM, Brenner MK, Barrett AJ, Heslop HE. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2. PMID: 20709906.
      Citations: 58     Fields:    Translation:HumansCells
    137. Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15. PMID: 20506146.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    138. Shafer JA, Cruz CR, Leen AM, Ku S, Lu A, Rousseau A, Heslop HE, Rooney CM, Bollard CM, Foster AE. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010 May; 51(5):870-80. PMID: 20367572.
      Citations: 17     Fields:    Translation:HumansCells
    139. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK, Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70. PMID: 20428207.
      Citations: 170     Fields:    Translation:HumansAnimalsCells
    140. Shafer JA, Heslop HE, Brenner MK, Carrum G, Wu MF, Liu H, Ahmed N, Gottschalk S, Kamble R, Leung KS, Myers GD, Bollard CM, Krance RA. Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leuk Lymphoma. 2010 Apr; 51(4):664-70. PMID: 20367182.
      Citations: 6     Fields:    Translation:Humans
    141. Heslop HE. Safer CARS. Mol Ther. 2010 Apr; 18(4):661-2. PMID: 20357776.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    142. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, Wilson J, Dotti G, Heslop HE, Leen AM, Rooney CM. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010 Apr; 33(3):305-15. PMID: 20445351.
      Citations: 64     Fields:    Translation:HumansCells
    143. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Gottschalk SM, Bollard CM, Heslop HE, Brenner MK, Krance RA. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81. PMID: 20348004.
      Citations: 16     Fields:    Translation:Humans
    144. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7. PMID: 20171074.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    145. Schriber JR, Anasetti C, Heslop HE, Leahigh AK. Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. Biol Blood Marrow Transplant. 2010 May; 16(5):595-7. PMID: 20167277.
      Citations: 6     Fields:    Translation:Humans
    146. Ahmed N, Heslop HE, Mackall CL. T-cell-based therapies for malignancy and infection in childhood. Pediatr Clin North Am. 2010 Feb; 57(1):83-96. PMID: 20307713.
      Citations: 3     Fields:    Translation:HumansCells
    147. Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703. PMID: 20110422.
      Citations: 41     Fields:    Translation:HumansCells
    148. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Goodell MA, Heslop HE, Brenner MK. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010 Mar; 24(3):563-72. PMID: 20072155.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    149. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 Jan 15; 16(2):474-85. PMID: 20068073.
      Citations: 119     Fields:    Translation:HumansAnimalsCells
    150. Gao X, Xue Z, Xing J, Lee DY, Gottschalk SM, Heslop HE, Bollard CM, Wong ST. Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging. Acad Radiol. 2010 Apr; 17(4):479-88. PMID: 20060747.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    151. Foster AE, Okur FV, Biagi E, Lu A, Dotti G, Yvon E, Savoldo B, Carrum G, Andreeff M, Goodell MA, Heslop HE, Brenner MK. Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer. 2009 Nov 18; 8:106. PMID: 19922650.
      Citations: 3     Fields:    Translation:HumansCells
    152. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35. PMID: 19880495.
      Citations: 276     Fields:    Translation:HumansCellsCTClinical Trials
    153. Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, Horowitz MM, Rizzo JD, Heslop HE, Anasetti C, Maziarz RT. Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1493-501. PMID: 19781658.
      Citations: 8     Fields:    Translation:Humans
    154. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, Savoldo B. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91. PMID: 19759356.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    155. Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009 Nov 05; 114(19):4002-8. PMID: 19724053.
      Citations: 82     Fields:    Translation:HumansCells
    156. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92. PMID: 19700662.
      Citations: 124     Fields:    Translation:HumansCellsCTClinical Trials
    157. Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, Dilloo D, Heslop HE, Brenner MK, Rooney CM, Leen AM. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25. PMID: 19584818.
      Citations: 32     Fields:    Translation:HumansCells
    158. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87. PMID: 19532139.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    159. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67. PMID: 19443656.
      Citations: 83     Fields:    Translation:HumansCells
    160. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G, Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402. PMID: 19377047.
      Citations: 159     Fields:    Translation:HumansAnimalsCells
    161. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8. PMID: 19259067.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    162. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70. PMID: 18978797.
      Citations: 473     Fields:    Translation:HumansCells
    163. Ahmed N, Leung KS, Rosenblatt H, Bollard CM, Gottschalk S, Myers GD, Carrum G, Heslop HE, Brenner MK, Krance RA. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304. PMID: 18940685.
      Citations: 7     Fields:    Translation:Humans
    164. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, Liu H, Heslop HE, Brenner MK, Krance RA. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52. PMID: 18940679.
      Citations: 24     Fields:    Translation:HumansCells
    165. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50. PMID: 18971421.
      Citations: 48     Fields:    Translation:HumansCellsCTClinical Trials
    166. Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008 Oct 21; 71(17):1326-34. PMID: 18936424.
      Citations: 32     Fields:    Translation:Humans
    167. Heslop HE, Brenner MK. The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1. PMID: 18725876.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    168. Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop HE, Brenner MK, Rooney CM. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74. PMID: 18600178.
      Citations: 9     Fields:    Translation:HumansCells
    169. Bollard CM, Cooper LJ, Heslop HE. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008 Sep; 21(3):405-20. PMID: 18790446.
      Citations: 10     Fields:    Translation:HumansCells
    170. Leen AM, Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol. 2008 Oct; 143(2):169-79. PMID: 18691164.
      Citations: 12     Fields:    Translation:HumansCells
    171. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008 Sep 01; 112(5):1876-85. PMID: 18591381.
      Citations: 43     Fields:    Translation:HumansCells
    172. Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5. PMID: 18463534.
      Citations: 90     Fields:    Translation:HumansAnimalsCells
    173. Craddock J, Heslop HE. Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens. Update Cancer Ther. 2008 Mar; 3(1):33-41. PMID: 19255606.
      Citations:    
    174. Pule MA, Rousseau A, Vera J, Heslop HE, Brenner MK, Vanin EF. Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences. Cytotherapy. 2008; 10(5):526-39. PMID: 18821360.
      Citations: 6     Fields:    Translation:HumansCells
    175. Cairo MS, Heslop H. Pediatric blood and marrow transplantation: state of the science. Bone Marrow Transplant. 2008 Jan; 41(2):97. PMID: 18231112.
      Citations: 4     Fields:    Translation:Humans
    176. Falkenburg JH, Heslop HE, Barrett AJ. T cell therapy in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):136-41. PMID: 18162234.
      Citations: 3     Fields:    Translation:HumansCells
    177. Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant. 2008 Jan; 41(2):193-8. PMID: 17982497.
      Citations: 26     Fields:    Translation:HumansCells
    178. Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1268-85. PMID: 17950914.
      Citations: 9     Fields:    Translation:Humans
    179. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan; 82(1):546-54. PMID: 17942545.
      Citations: 58     Fields:    Translation:HumansCells
    180. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802. PMID: 17638856.
      Citations: 85     Fields:    Translation:HumansAnimalsCells
    181. Kamble RT, Clark DA, Leong HN, Heslop HE, Brenner MK, Carrum G. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(6):563-6. PMID: 17637686.
      Citations: 14     Fields:    Translation:HumansCells
    182. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45. PMID: 17609424.
      Citations: 148     Fields:    Translation:HumansCellsCTClinical Trials
    183. Louis CU, Paulino AC, Gottschalk S, Bertuch AA, Chintagumpala M, Heslop HE, Russell HV. A single institution experience with pediatric nasopharyngeal carcinoma: high incidence of toxicity associated with platinum-based chemotherapy plus IMRT. J Pediatr Hematol Oncol. 2007 Jul; 29(7):500-5. PMID: 17609631.
      Citations: 6     Fields:    Translation:Humans
    184. Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64. PMID: 17575166.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    185. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):913-24. PMID: 17640595.
      Citations: 91     Fields:    Translation:HumansCells
    186. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30. PMID: 17507664.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    187. Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE, Leen AM. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):677-86. PMID: 17417664.
      Citations: 15     Fields:    Translation:HumansCells
    188. Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9. PMID: 17401392.
      Citations: 18     Fields:    Translation:HumansCells
    189. Heslop HE. Gene therapy. Cytotherapy. 2007; 9(6):519-20. PMID: 17882715.
      Citations:    Fields:    Translation:Humans
    190. Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, Carrum G, Khan SP, Heslop HE, Brenner MK, Bollard CM, Krance RA. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84. PMID: 17162209.
      Citations: 24     Fields:    Translation:HumansCells
    191. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007 Mar 15; 109(6):2657-62. PMID: 17110457.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    192. Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, Caldwell YM, Gee AP, Scott JD, Savoldo B. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant. 2006 Nov-Dec; 20(6):689-94. PMID: 17100717.
      Citations: 9     Fields:    Translation:HumansCells
    193. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6. PMID: 16998485.
      Citations: 222     Fields:    Translation:HumansCells
    194. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK, Dotti G. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7. PMID: 16926291.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    195. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9. PMID: 16835376.
      Citations: 72     Fields:    Translation:HumansCells
    196. Ahmed N, Heslop HE. Viral lymphomagenesis. Curr Opin Hematol. 2006 Jul; 13(4):254-9. PMID: 16755222.
      Citations: 2     Fields:    Translation:HumansCells
    197. Heslop HE. Commentary on journal of immunotherapy paper by melenhorst et al. J Immunother. 2006 Jul-Aug; 29(4):365-6. PMID: 16799331.
      Citations:    Fields:    Translation:HumansCells
    198. Tey SK, Bollard CM, Heslop HE. Adoptive T-cell transfer in cancer immunotherapy. Immunol Cell Biol. 2006 Jun; 84(3):281-9. PMID: 16681825.
      Citations: 16     Fields:    Translation:HumansCells
    199. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E, Brenner MK. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808. PMID: 16741253.
      Citations: 76     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    200. Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Scott JD, Goss JA. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006 May-Jun; 20(3):389-93. PMID: 16824159.
      Citations: 13     Fields:    Translation:HumansCells
    201. Jones RB, Anasetti C, Appel P, DiPersio J, Heslop H, Lemaistre F, Silver S, Sirilla J, Stiff P. ASBMT committee report: white paper on measurement of quality outcomes. Biol Blood Marrow Transplant. 2006 May; 12(5):594-7. PMID: 16635795.
      Citations: 1     Fields:    Translation:Humans
    202. Lacuesta K, Buza E, Hauser H, Granville L, Pule M, Corboy G, Finegold M, Weiss H, Chen SY, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60. PMID: 16699368.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    203. Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May; 47(5):837-42. PMID: 16753867.
      Citations: 11     Fields:    Translation:HumansCells
    204. Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK, Carrum G. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant. 2006 Mar; 37(6):547-52. PMID: 16462757.
      Citations: 6     Fields:    Translation:Humans
    205. Bollard CM, Huls MH, Buza E, Weiss H, Torrano V, Gresik MV, Chang J, Gee A, Gottschalk SM, Carrum G, Brenner MK, Rooney CM, Heslop HE. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7. PMID: 16507214.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    206. Gottschalk S, Bollard CM, Straathof KC, Louis CU, Savoldo B, Dotti G, Brenner MK, Heslop HE, Rooney CM. T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82. PMID: 17824182.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    207. Leen AM, Myers GD, Bollard CM, Huls MH, Sili U, Gee AP, Heslop HE, Rooney CM. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15. PMID: 16461793.
      Citations: 10     Fields:    Translation:HumansCells
    208. Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE, Bollard CM. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005 Dec; 36(11):1001-8. PMID: 16184180.
      Citations: 27     Fields:    Translation:Humans
    209. Hale GA, Bowman LC, Rochester RJ, Benaim E, Heslop HE, Krance RA, Horwitz EM, Cunningham JM, Tong X, Srivastava DK, Handgretinger R, Jones DP. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant. 2005 Nov; 11(11):912-20. PMID: 16275594.
      Citations: 14     Fields:    Translation:HumansCells
    210. Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE, Brenner MK, Popat U. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant. 2005 Nov; 36(9):797-802. PMID: 16151431.
      Citations: 9     Fields:    Translation:HumansCells
    211. Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332-41. PMID: 16249392.
      Citations: 20     Fields:    Translation:HumansCells
    212. Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, Rooney CM, Bollard CM. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005 Sep 15; 175(6):4137-47. PMID: 16148164.
      Citations: 30     Fields:    Translation:HumansCells
    213. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005 Sep; 5(9):2222-8. PMID: 16095501.
      Citations: 36     Fields:    Translation:HumansCells
    214. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41. PMID: 15979412.
      Citations: 177     Fields:    Translation:HumansCells
    215. Popat U, Carrum G, May R, Lamba R, Krance RA, Heslop HE, Brenner MK. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32. PMID: 15834432.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    216. Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005 Mar; 5(3):566-72. PMID: 15707412.
      Citations: 23     Fields:    Translation:HumansCells
    217. Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54. PMID: 15728125.
      Citations: 225     Fields:    Translation:HumansAnimalsCells
    218. Heslop HE. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program. 2005; 260-6. PMID: 16304390.
      Citations: 35     Fields:    Translation:HumansCells
    219. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005; 56:29-44. PMID: 15660500.
      Citations: 124     Fields:    Translation:HumansCells
    220. Dotti G, Heslop HE. Current status of genetic modification of T cells for cancer treatment. Cytotherapy. 2005; 7(3):262-72. PMID: 16081353.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    221. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005 Jan; 46(1):1-10. PMID: 15621775.
      Citations: 38     Fields:    Translation:Humans
    222. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004 Dec 20; 200(12):1623-33. PMID: 15611290.
      Citations: 120     Fields:    Translation:HumansCells
    223. Yotnda P, Zompeta C, Heslop HE, Andreeff M, Brenner MK, Marini F. Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenoviruses. Hum Gene Ther. 2004 Dec; 15(12):1229-42. PMID: 15684699.
      Citations: 9     Fields:    Translation:HumansCells
    224. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood. 2005 Mar 01; 105(5):1898-904. PMID: 15542583.
      Citations: 110     Fields:    Translation:HumansCellsCTClinical Trials
    225. Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004 Sep 15; 78(5):755-7. PMID: 15371682.
      Citations: 9     Fields:    Translation:HumansCells
    226. Heslop HE, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol. 2004 Sep; 17(3):401-13. PMID: 15498712.
      Citations: 5     Fields:    Translation:HumansCells
    227. Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27. PMID: 15235393.
      Citations: 27     Fields:    Translation:HumansCells
    228. Heslop HE, Gottschalk SM, Bollard CM, Straathof KC, Huls MH, Brenner MK, Rooney CM. Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4. PMID: 15209923.
      Citations:    Fields:    Translation:HumansCells
    229. Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004 Mar; 10(3):143-55. PMID: 14993880.
      Citations: 22     Fields:    Translation:HumansCells
    230. Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, Land GA, Heslop H, Brenner M, Zhang JZ. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008. PMID: 14985264.
      Citations: 19     Fields:    Translation:HumansCells
    231. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, Rooney CM, Wang RF. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004 Feb 16; 199(4):459-70. PMID: 14769850.
      Citations: 54     Fields:    Translation:HumansCells
    232. Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004 Feb; 11(2):81-91. PMID: 14685154.
      Citations: 26     Fields:    Translation:HumansCells
    233. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81. PMID: 14751931.
      Citations: 43     Fields:    Translation:HumansCells
    234. Ganguly S, Carrum G, Nizzi F, Heslop HE, Popat U. Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemia. Am J Hematol. 2004 Jan; 75(1):48-51. PMID: 14695632.
      Citations: 3     Fields:    Translation:HumansCells
    235. Hale GA, Rochester RJ, Heslop HE, Krance RA, Gingrich JR, Benaim E, Horwitz EM, Cunningham JM, Tong X, Srivastava DK, Leung WH, Woodard P, Bowman LC, Handgretinger R. Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome. Biol Blood Marrow Transplant. 2003 Nov; 9(11):698-705. PMID: 14652853.
      Citations: 12     Fields:    Translation:Humans
    236. Hale GA, Bowman LC, Woodard JP, Cunningham JM, Benaim E, Horwitz EM, Heslop HE, Krance RA, Leung W, Shearer PD, Handgretinger R. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant. 2003 Jun; 31(11):981-6. PMID: 12774048.
      Citations:    Fields:    Translation:HumansCells
    237. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED, Bollard C, Michalek J, Ghetie V, Heslop HE, Molldrem JJ, Rooney CM, Schlinder J, Vitetta E, Brenner MK. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9. PMID: 12763937.
      Citations: 39     Fields:    Translation:HumansCells
    238. Sili U, Huls MH, Davis AR, Gottschalk S, Brenner MK, Heslop HE, Rooney CM. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003 May-Jun; 26(3):241-56. PMID: 12806278.
      Citations: 20     Fields:    Translation:HumansCells
    239. Brenner MK, Wulf GG, Rill DR, Luo KL, Goodell MA, Mei Z, Kuehnle I, Brown MP, Pule M, Heslop HE, Krance RA. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8. PMID: 12799286.
      Citations: 7     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    240. Krance RA, Kuehnle I, Rill DR, Mei Z, Pinetta C, Evans W, Brown MP, Pulé M, Heslop HE, Brenner MK. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81. PMID: 12720220.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    241. Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev. 2003 Feb; 29(1):3-10. PMID: 12633575.
      Citations: 3     Fields:    Translation:Humans
    242. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am Soc Hematol Educ Program. 2003; 331-49. PMID: 14633789.
      Citations: 16     Fields:    Translation:HumansCells
    243. Brenner MK, Heslop HE. Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3. PMID: 12850996.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    244. Straathof KC, Bollard CM, Rooney CM, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist. 2003; 8(1):83-98. PMID: 12604735.
      Citations: 7     Fields:    Translation:HumansCells
    245. Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003; 110(2-3):139-48. PMID: 14583674.
      Citations: 7     Fields:    Translation:HumansCells
    246. Wagner HJ, Sili U, Gahn B, Vigouroux S, Huls MH, Xie W, Vignali D, Brenner MK, Heslop HE, Rooney CM. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy. 2003; 5(3):231-40. PMID: 12850791.
      Citations: 3     Fields:    Translation:HumansCells
    247. Huls MH, Rooney CM, Heslop HE. Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. Acta Haematol. 2003; 110(2-3):149-53. PMID: 14583675.
      Citations:    Fields:    Translation:HumansCells
    248. Voo KS, Fu T, Heslop HE, Brenner MK, Rooney CM, Wang RF. Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002 Dec 15; 62(24):7195-9. PMID: 12499257.
      Citations: 23     Fields:    Translation:HumansCells
    249. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003 Mar 01; 101(5):1905-12. PMID: 12411306.
      Citations: 62     Fields:    Translation:HumansCells
    250. Carter BA, Karpen SJ, Quiros-Tejeira RE, Chang IF, Clark BS, Demmler GJ, Heslop HE, Scott JD, Seu P, Goss JA. Intravenous Cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation. 2002 Oct 15; 74(7):1050-2. PMID: 12394854.
      Citations: 6     Fields:    Translation:HumansCells
    251. Pule M, Bollard CM, Heslop HE. Genetically engineered T-cells for adoptive immunotherapy. Curr Opin Mol Ther. 2002 Oct; 4(5):467-75. PMID: 12435048.
      Citations: 1     Fields:    Translation:HumansCells
    252. Straathof KC, Savoldo B, Heslop HE, Rooney CM. Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol. 2002 Sep; 118(3):728-40. PMID: 12181039.
      Citations: 6     Fields:    Translation:Humans
    253. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66. PMID: 12393655.
      Citations: 38     Fields:    Translation:HumansCellsCTClinical Trials
    254. Ringwald-Smith KA, Heslop HE, Krance RA, Mackert PW, Hancock ML, Stricklin LM, Bowman LC, Hale GA. Energy expenditure in children undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002 Jul; 30(2):125-30. PMID: 12132052.
      Citations: 5     Fields:    Translation:Humans
    255. Bollard CM, Rössig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, Brenner MK, Heslop HE, Rooney CM. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 01; 99(9):3179-87. PMID: 11964281.
      Citations: 125     Fields:    Translation:HumansCells
    256. Rodriguez V, Kuehnle I, Heslop HE, Khan S, Krance RA. Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002 Mar; 29(6):515-7. PMID: 11960272.
      Citations: 12     Fields:    Translation:HumansCells
    257. Rousseau R, Bollard C, Heslop H. [Contribution of antineoplastic biotherapy in the treatment of leukemia in children]. Arch Pediatr. 2002 Mar; 9(3):289-306. PMID: 11938542.
      Citations:    Fields:    Translation:HumansCells
    258. Savoldo B, Cubbage ML, Durett AG, Goss J, Huls MH, Liu Z, Teresita L, Gee AP, Ling PD, Brenner MK, Heslop HE, Rooney CM. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18. PMID: 11777989.
      Citations: 26     Fields:    Translation:HumansCells
    259. Wagner HJ, Rooney CM, Heslop HE. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(1):1-8. PMID: 11846351.
      Citations: 6     Fields:    Translation:Humans
    260. Gahn B, Hunt G, Rooney CM, Heslop HE. Immunotherapy to reconstitute immunity to DNA viruses. Semin Hematol. 2002 Jan; 39(1):41-7. PMID: 11799528.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    261. Heslop HE, Bollard CM, Gottschalk S, Kuehnle I, Huls MH, Gee AP, Brenner MK, Rooney CM. Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4. PMID: 12473214.
      Citations: 3     Fields:    Translation:HumansCells
    262. Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002; 159:123-33. PMID: 11785836.
      Citations: 17     Fields:    Translation:HumansCells
    263. Gottschalk S, Heslop HE, Roon CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res. 2002; 84:175-201. PMID: 11883527.
      Citations: 7     Fields:    Translation:HumansCells
    264. Sandlund JT, Bowman L, Heslop HE, Krance R, Mahmoud H, Pui C-, Hale G, Benaim E. Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refractory NHL. Cytotherapy. 2002; 4(3):253-8. PMID: 12194721.
      Citations: 3     Fields:    Translation:Humans
    265. Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE. Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42. PMID: 12611071.
      Citations: 8     Fields:    Translation:HumansCells
    266. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, Rifkin RM, Abhyankar S, Briggs AD, Burt R, Lipani J, Roskos LK, White JM, Havrilla N, Schwab G, Heslop HE. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001 Oct 01; 98(7):2052-8. PMID: 11567989.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    267. Savoldo B, Goss J, Liu Z, Huls MH, Doster S, Gee AP, Brenner MK, Heslop HE, Rooney CM. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001 Sep 27; 72(6):1078-86. PMID: 11579304.
      Citations: 18     Fields:    Translation:HumansCells
    268. Gahn B, Siller-Lopez F, Pirooz AD, Yvon E, Gottschalk S, Longnecker R, Brenner MK, Heslop HE, Aguilar-Cordova E, Rooney CM. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13. PMID: 11477583.
      Citations: 21     Fields:    Translation:HumansCells
    269. Heslop HE. Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation. J Immunother. 2001 Jul-Aug; 24(4):283-4. PMID: 11565828.
      Citations:    Fields:    Translation:HumansCells
    270. Rousseau RF, Bollard CM, Heslop HE. Gene therapy for paediatric leukaemia. Expert Opin Biol Ther. 2001 Jul; 1(4):663-74. PMID: 11727502.
      Citations: 1     Fields:    Translation:HumansCells
    271. Yotnda P, Onishi H, Heslop HE, Shayakhmetov D, Lieber A, Brenner M, Davis A. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001 Jun; 8(12):930-7. PMID: 11426333.
      Citations: 36     Fields:    Translation:HumansCells
    272. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001 Feb 15; 97(4):835-43. PMID: 11159505.
      Citations: 87     Fields:    Translation:HumansCells
    273. Hale GA, Tong X, Benaim E, Cunningham JM, Heslop HE, Horwiz EM, Leung W, Rochester RJ, Shearer PD, Srivastava DK, Woodard JP, Bowman LC. Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. Bone Marrow Transplant. 2001 Jan; 27(2):155-62. PMID: 11281384.
      Citations: 1     Fields:    Translation:Humans
    274. Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001; 258:221-9. PMID: 11443864.
      Citations: 11     Fields:    Translation:HumansCells
    275. Bollard CM, Heslop HE, Brenner MK. Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22. PMID: 11372750.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    276. Savoldo B, Heslop HE, Rooney CM. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. Leuk Lymphoma. 2000 Nov; 39(5-6):455-64. PMID: 11342329.
      Citations: 2     Fields:    Translation:HumansCells
    277. Brenner MK, Heslop H, Krance R, Horowitz M, Strother D, Nuchtern J, Grilley B, Martingano E, Cooper K. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88. PMID: 10910144.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    278. Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75. PMID: 10910143.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    279. Heslop HE. Gene therapy of pediatric leukemia. Clin Lab Med. 2000 Mar; 20(1):183-95, x. PMID: 10702902.
      Citations:    Fields:    Translation:HumansCells
    280. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5. PMID: 10666232.
      Citations: 38     Fields:    Translation:HumansCells
    281. Hale GA, Heslop HE, Bowman LC, Rochester RA, Pui CH, Brenner MK, Krance RA. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant. 1999 Oct; 24(7):735-9. PMID: 10516676.
      Citations: 8     Fields:    Translation:Humans
    282. Heslop HE. Haemopoietic stem cell transplantation from unrelated donors. Br J Haematol. 1999 Apr; 105(1):2-6. PMID: 10366243.
      Citations:    Fields:    Translation:Humans
    283. Aguilar LK, Rooney CM, Heslop HE. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol. 1999 Mar; 11(2):96-101. PMID: 10188073.
      Citations: 5     Fields:    Translation:HumansCells
    284. Hale GA, Heslop HE, Krance RA, Brenner MA, Jayawardene D, Srivastava DK, Patrick CC. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999 Feb; 23(3):277-82. PMID: 10084260.
      Citations: 38     Fields:    Translation:Humans
    285. Heslop HE, Perez M, Benaim E, Rochester R, Brenner MK, Rooney CM. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher. 1999; 14(3):154-6. PMID: 10540372.
      Citations: 3     Fields:    Translation:HumansCells
    286. Moriwaki K, Sutton RE, Perez M, Brenner MK, Heslop HE. Transduction of CD34(+) and CD34(-)/lin(-) hemopoietic progenitors by lentivirus vectors. Cytotherapy. 1999; 1(6):433-8. PMID: 20426543.
      Citations:    Fields:    Translation:HumansCells
    287. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55. PMID: 9716582.
      Citations: 241     Fields:    Translation:HumansCells
    288. Fletcher BD, Heslop HE, Kaste SC, Bodner S. Upper airway obstruction and pulmonary abnormalities due to lymphoproliferative disease following bone marrow transplantation in children. Pediatr Radiol. 1998 Jul; 28(7):492-6. PMID: 9662565.
      Citations:    Fields:    Translation:HumansCells
    289. Hutchings M, Moriwaki K, Dilloo D, Hoffmann T, Kimbrough S, Johnsen HE, Brenner MK, Heslop HE. Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells. J Hematother. 1998 Jun; 7(3):217-24. PMID: 9621255.
      Citations: 1     Fields:    Translation:HumansCells
    290. Roskrow MA, Rooney CM, Heslop HE, Brenner MK, Krance RA, Gresik MV, McClain K, Aguilar LK, Grilley B, Rob E, Carrum G. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50. PMID: 9625264.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    291. Roskrow MA, Suzuki N, Gan Yj, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998 Apr 15; 91(8):2925-34. PMID: 9531603.
      Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
    292. Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998; (23):89-93. PMID: 9709309.
      Citations: 9     Fields:    Translation:HumansCells
    293. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32. PMID: 9926252.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    294. Brenner MK, Heslop HE, Rooney CM. Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90. PMID: 9704428.
      Citations:    Fields:    Translation:HumansCells
    295. Rooney CM, Heslop HE, Brenner MK. EBV specific CTL: a model for immune therapy. Vox Sang. 1998; 74 Suppl 2:497-8. PMID: 9704488.
      Citations: 4     Fields:    Translation:HumansCells
    296. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Boucher RC, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1997 Dec 10; 8(18):2301-38. PMID: 9449381.
      Citations: 4     Fields:    Translation:Humans
    297. Kauffman WM, Heslop HE, Gronemeyer SA, Chen G, Krance RA. Hepatic arterial resistance index--an indicator of diffuse liver disease in children treated with bone marrow transplantation. Clin Radiol. 1997 Dec; 52(12):903-6. PMID: 9413962.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    298. Hongeng S, Krance RA, Bowman LC, Srivastava DK, Cunningham JM, Horwitz EM, Brenner MK, Heslop HE. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet. 1997 Sep 13; 350(9080):767-71. PMID: 9297996.
      Citations: 14     Fields:    Translation:Humans
    299. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997 Jun; 157:217-22. PMID: 9255632.
      Citations: 32     Fields:    Translation:HumansCells
    300. Rooney CM, Smith CA, Heslop HE. Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today. 1997 Jan; 3(1):24-30. PMID: 9021739.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    301. Comoli P, Dilloo D, Hutchings M, Hoffma T, Heslop HE. Measuring gene-transfer efficiency. Nat Med. 1996 Dec; 2(12):1280-1. PMID: 8946816.
      Citations:    Fields:    Translation:HumansCells
    302. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Tiberghien P, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Dec 01; 7(18):2287-313. PMID: 8953320.
      Citations: 1     Fields:    Translation:Humans
    303. Smith CA, Ng CY, Loftin SK, Li C, Heslop HE, Brenner MK, Rooney CM. Adoptive immunotherapy for Epstein-Barr virus-related lymphoma. Leuk Lymphoma. 1996 Oct; 23(3-4):213-20. PMID: 9031101.
      Citations: 5     Fields:    Translation:HumansCells
    304. Brenner MK, Heslop HE, Rill D, Li C, Smith C, Krance R, Rooney C. Transfer of marker genes into hemopoietic progenitor cells. Cytokines Mol Ther. 1996 Sep; 2(3):193-200. PMID: 9384704.
      Citations:    Fields:    Translation:HumansCells
    305. Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Ledley FD, Lotze MT, Wilson JM, Nabel GJ, Cornetta K, Economou JS, Freeman SM, Riddell SR, Oldfield E, Gansbacher B, Dunbar C, Walker RE, Schuening FG, Roth JA, Crystal RG, Welsh MJ, Culver K, Heslop HE, Simons J, Wilmott RW, Aebischer P, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Aug 20; 7(13):1621-47. PMID: 8864763.
      Citations: 1     Fields:    Translation:Humans
    306. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May; 2(5):551-5. PMID: 8616714.
      Citations: 166     Fields:    Translation:HumansCells
    307. Heslop HE, Brenner MK, Krance RA, Bowman L, Cunningham JM, Richardson S, Alexander B, Heideman R, Boyett JM, Srivastava DK, Marcus SG, Berenson R, Heimfeld S, Brown S. Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum Gene Ther. 1996 Mar 20; 7(5):655-67. PMID: 8845391.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    308. Cela ME, Holladay MS, Rooney CM, Richardson S, Alexander B, Krance RA, Brenner MK, Heslop HE. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7. PMID: 8640174.
      Citations: 8     Fields:    Translation:HumansCells
    309. Heslop HE, Rooney CM, Rill DR, Krance RA, Brenner MK. Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13. PMID: 8706035.
      Citations: 2     Fields:    Translation:HumansCells
    310. Heslop HE, Rooney CM, Brenner MK. Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5. PMID: 8839397.
      Citations: 1     Fields:    Translation:Humans
    311. Pui CH, Relling MV, Rivera GK, Hancock ML, Raimondi SC, Heslop HE, Santana VM, Ribeiro RC, Sandlund JT, Mahmoud HH, et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia. 1995 Dec; 9(12):1990-6. PMID: 8609707.
      Citations: 13     Fields:    Translation:Humans
    312. Kauffman WM, Zuckerman SL, Heslop HE, Krance RA. Portal venous Doppler findings in a bone marrow transplant patient with cardiac tamponade. J Ultrasound Med. 1995 Nov; 14(11):877-9. PMID: 8551557.
      Citations:    Fields:    Translation:Humans
    313. Heslop HE, Roskrow M. Gene transfer for the therapy of hematologic malignancy. Curr Opin Hematol. 1995 Nov; 2(6):417-22. PMID: 9372030.
      Citations: 1     Fields:    Translation:HumansCells
    314. Heslop HE, Benaim E, Brenner MK, Krance RA, Stricklin LM, Rochester RJ, Billing R. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6. PMID: 7674747.
      Citations: 3     Fields:    Translation:HumansCells
    315. Smith FS, Rencher SD, Heslop HE, Hurwitz JL. T cell receptor repertoire of CD4+ and CD8+ T cell subsets in the allogeneic bone marrow transplant recipient. Cancer Immunol Immunother. 1995 Aug; 41(2):104-10. PMID: 7656269.
      Citations: 2     Fields:    Translation:HumansCells
    316. Phipps S, Brenner M, Heslop H, Krance R, Jayawardene D, Mulhern R. Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study. Bone Marrow Transplant. 1995 Jun; 15(6):829-35. PMID: 7581077.
      Citations: 7     Fields:    Translation:Humans
    317. Smith CA, Ng CY, Heslop HE, Holladay MS, Richardson S, Turner EV, Loftin SK, Li C, Brenner MK, Rooney CM. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9. PMID: 7633844.
      Citations: 40     Fields:    Translation:HumansCells
    318. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13. PMID: 7799740.
      Citations: 216     Fields:    Translation:HumansCells
    319. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103. PMID: 7833284.
      Citations: 24     Fields:    Translation:HumansCells
    320. Brenner MK, Cunningham JM, Sorrentino BP, Heslop HE. Gene transfer into human hemopoietic progenitor cells. Br Med Bull. 1995 Jan; 51(1):167-91. PMID: 7767642.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    321. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994 Sep 08; 331(10):679-80. PMID: 8052285.
      Citations: 57     Fields:    Translation:HumansCells
    322. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994 Jul 15; 84(2):380-3. PMID: 8025266.
      Citations: 37     Fields:    Translation:HumansCells
    323. Brenner MK, Rill DR, Moen RC, Krance RA, Heslop HE, Mirro J, Anderson WF, Ihle JN. Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci. 1994 May 31; 716:204-14; discussion 214-5, 225-7. PMID: 8024195.
      Citations: 5     Fields:    Translation:HumansCells
    324. Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5. PMID: 7519937.
      Citations: 4     Fields:    Translation:HumansCells
    325. Brenner M, Krance R, Heslop HE, Santana V, Ihle J, Ribeiro R, Roberts WM, Mahmoud H, Boyett J, Moen RC, et al. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99. PMID: 8049305.
      Citations: 1     Fields:    Translation:HumansCells
    326. Heslop HE, Li C, Krance RA, Loftin SK, Rooney CM. Epstein-Barr infection after bone marrow transplantation. Blood. 1994 Mar 15; 83(6):1706-8. PMID: 8123864.
      Citations: 3     Fields:    Translation:HumansCells
    327. Heslop HE. Cytokine gene transfer in the therapy of malignancy. Baillieres Clin Haematol. 1994 Mar; 7(1):135-51. PMID: 8038497.
      Citations:    Fields:    Translation:HumansAnimalsCells
    328. Heslop HE, Brenner MK, Rooney C, Krance RA, Roberts WM, Rochester R, Smith CA, Turner V, Sixbey J, Moen R, et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994 Mar; 5(3):381-97. PMID: 8018749.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    329. Mathew P, Bozeman P, Krance RA, Brenner MK, Heslop HE. Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994 Feb; 13(2):221-3. PMID: 8205095.
      Citations: 4     Fields:    Translation:Humans
    330. Brenner MK, Heslop HE, Rill D, Li C, Nilson T, Roberts M, Smith C, Krance R, Rooney C. Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7. PMID: 7587132.
      Citations: 1     Fields:    Translation:HumansCells
    331. Brenner MK, Rill DR, Heslop HE, Rooney CM, Roberts WM, Li C, Nilson T, Krance RA. Gene marking after bone marrow transplantation. Eur J Cancer. 1994; 30A(8):1171-6. PMID: 7654451.
      Citations: 3     Fields:    Translation:HumansCells
    332. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993 Nov 06; 342(8880):1134-7. PMID: 7901474.
      Citations: 37     Fields:    Translation:Humans
    333. Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 1993 Sep 04; 342(8871):587-8. PMID: 8102723.
      Citations: 5     Fields:    Translation:Humans
    334. Heslop HE, Hoffbrand AV, Brenner MK. TNF and chronic B lymphoproliferative disorders. Leukemia. 1993 Sep; 7(9):1476. PMID: 8371597.
      Citations: 1     Fields:    Translation:Humans
    335. Krance R, Heslop HE, Mahmoud H, Ribeiro R, Douglass E, Hurwitz C, Santana V, Kun L, Horowitz MM, Brenner MK. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplant. 1993 Jan; 11(1):33-6. PMID: 8431709.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    336. Rencher SD, Hanif I, Heslop HE, Turner VE, Brenner MK, Hurwitz JL. Reconstitution of the T cell receptor alpha beta repertoire in recipients of allogeneic BMT. Bone Marrow Transplant. 1992 Dec; 10(6):521-7. PMID: 1490202.
      Citations: 1     Fields:    Translation:HumansCells
    337. Gottlieb DJ, Prentice HG, Heslop HE, Bello C, Brenner MK. IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol. 1992 Mar; 87(3):493-8. PMID: 1544235.
      Citations: 4     Fields:    Translation:HumansAnimals
    338. Brenner MK, Heslop HE. Immunotherapy of leukemia. Leukemia. 1992; 6 Suppl 1:76-9. PMID: 1548941.
      Citations:    Fields:    Translation:Humans
    339. Brenner MK, Heslop HE. Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7. PMID: 1836732.
      Citations:    Fields:    Translation:HumansAnimalsCells
    340. Heslop HE, Brenner MK, Ganeshaguru K, Hoffbrand AV. Possible mechanism of action of interferon alpha in chronic B-cell malignancies. Br J Haematol. 1991 Oct; 79 Suppl 1:14-6. PMID: 1931702.
      Citations: 1     Fields:    Translation:HumansCells
    341. Brenner MK, Heslop HE. Graft versus leukaemia effects after marrow transplantation in man. Baillieres Clin Haematol. 1991 Jul; 4(3):727-49. PMID: 1958889.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    342. Oblakowski P, Bello-Fernandez C, Reittie JE, Heslop HE, Galatowicz G, Veys P, Wilkes S, Prentice HG, Hazlehurst G, Hoffbrand AV, et al. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells. Blood. 1991 May 01; 77(9):1996-2001. PMID: 1708296.
      Citations: 4     Fields:    Translation:HumansCells
    343. Katzav S, Cleveland JL, Heslop HE, Pulido D. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol. 1991 Apr; 11(4):1912-20. PMID: 2005887.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    344. Bello-Fernandez C, Bird C, Heslop HE, Gottlieb DJ, Reittie JE, Rill DM, Holland M, Prentice HG, Brenner MK. Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function. Blood. 1991 Mar 15; 77(6):1283-9. PMID: 1900445.
      Citations: 1     Fields:    Translation:HumansCells
    345. Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Hoffbrand AV, Brenner MK. Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration. Transplant Proc. 1991 Feb; 23(1 Pt 2):1704-5. PMID: 1989334.
      Citations: 1     Fields:    Translation:HumansCells
    346. Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol. 1991 Feb; 77(2):237-44. PMID: 2004026.
      Citations: 4     Fields:    Translation:Humans
    347. Heslop HE, Bianchi AC, Cordingley FT, Turner M, Chandima W, De Mel CP, Hoffbrand AV, Brenner MK. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990 Dec 01; 172(6):1729-34. PMID: 2258703.
      Citations: 12     Fields:    Translation:HumansCells
    348. Duncombe AS, Meager A, Prentice HG, Grundy JE, Heslop HE, Hoffbrand AV, Brenner MK. Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus. Blood. 1990 Sep 01; 76(5):1046-53. PMID: 2168224.
      Citations: 4     Fields:    Translation:HumansCells
    349. Gottlieb DJ, Prentice HG, Mehta AB, Galazka AR, Heslop HE, Hoffbrand AV, Brenner MK. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br J Haematol. 1990 Aug; 75(4):499-505. PMID: 2119792.
      Citations: 4     Fields:    Translation:HumansCells
    350. Wimperis JZ, Gottlieb D, Duncombe AS, Heslop HE, Prentice HG, Brenner MK. Requirements for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol. 1990 Jan 15; 144(2):541-7. PMID: 2136894.
      Citations: 9     Fields:    Translation:HumansCells
    351. Browett PJ, Heslop HE, Mehta AB, Norton JD. The t(9;22) translocation in Philadelphia-positive essential thrombocythaemia does not involve the T lymphocyte lineage. Acta Haematol. 1990; 83(4):203-5. PMID: 2142847.
      Citations:    Fields:    Translation:HumansCells
    352. Gignac SM, Buschle M, Heslop HE, Brenner MK, Hoffbrand AV, Drexler HG. Delayed Induction of Proto-Oncogene Expression in B-CLL Cells by Tumor Necrosis Factor. Leuk Lymphoma. 1990; 3(1):37-43. PMID: 27457196.
      Citations:    Fields:    
    353. Duncombe AS, Heslop HE, Turner M, Meager A, Priest R, Exley T, Brenner MK. Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol. 1989 Dec 01; 143(11):3828-34. PMID: 2584719.
      Citations: 8     Fields:    Translation:HumansCells
    354. Bianchi AC, Heslop HE, Veys P, Macey M, Holland M, Prentice HG, Brenner MK. Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. Br J Haematol. 1989 Dec; 73(4):468-74. PMID: 2692692.
      Citations:    Fields:    Translation:HumansCells
    355. Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989 Nov 15; 74(7):2335-42. PMID: 2804369.
      Citations: 11     Fields:    Translation:HumansCells
    356. Gottlieb DJ, Brenner MK, Heslop HE, Bianchi AC, Bello-Fernandez C, Mehta AB, Newland AC, Galazka AR, Scott EM, Hoffbrand AV, et al. A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer. 1989 Oct; 60(4):610-5. PMID: 2803933.
      Citations: 11     Fields:    Translation:Humans
    357. Heslop HE, Gottlieb DJ, Bianchi AC, Meager A, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989 Sep; 74(4):1374-80. PMID: 2504308.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    358. Heslop HE, Gottlieb DJ, Reittie JE, Bello-Fernandez C, Meager A, Prentice HG, Brenner MK. Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy. Br J Haematol. 1989 Jun; 72(2):122-6. PMID: 2503022.
      Citations: 6     Fields:    Translation:HumansCells
    359. Reittie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Prentice HG, Brenner MK. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8. PMID: 2495037.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    360. Heslop HE, Price GM, Prentice HG, Cordingley FT, Webster AD, Hoffbrand AV, Brenner MK. In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. J Immunol. 1988 May 15; 140(10):3461-6. PMID: 3283234.
      Citations: 2     Fields:    Translation:HumansCells
    361. Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988 Apr 30; 1(8592):969-71. PMID: 2896830.
      Citations: 39     Fields:    Translation:HumansCells
    362. Bianchi AC, Heslop HE, Drexler HG, Cordingley FT, Turner M, De Mel WC, Hoffbrand AV, Brenner MK. Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies. Nouv Rev Fr Hematol. 1988; 30(5-6):317-9. PMID: 3265501.
      Citations: 1     Fields:    Translation:HumansCells
    363. Heslop HE, Heaton DC, Hart DN, Allen JR, Abbott GD, Beard ME. Allogeneic bone marrow transplantation at Christchurch 1979-1985. N Z Med J. 1986 May 14; 99(801):318-21. PMID: 3520412.
      Citations:    Fields:    Translation:Humans
    HESLOP's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (794)
    Explore
    _
    Co-Authors (108)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _